1
|
Abstract
With the rapid pace of immunologic research, it is more important than ever for readers to understand rational immunodiagnosis, immunopro-phylaxis, and immunotherapy. This column is intended to help you ensure proper immunologic drug use in your practice.
Collapse
Affiliation(s)
- John D. Grabenstein
- U.S. Army Medical Department, c/o School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7360 (919-962-0106)
| | | |
Collapse
|
2
|
Abstract
Solid organ and hematopoietic stem cell transplant recipients may be exposed to diseases which may be prevented through live attenuated virus vaccines (LAVV). Because of their immunosuppression, these diseases can lead to severe complications in transplant recipients. Despite increasing evidence regarding the safety and effectiveness of certain LAVV, these vaccines are still contraindicated for immunocompromised patients, such as transplant recipients. We review the available studies on LAVV, such as varicella zoster, measles-mumps-rubella, influenza, yellow fever, polio, and Japanese encephalitis vaccines in transplant patients. We discuss the current recommendations and the potential risks, as well as the expected benefits of LAVV immunization in this population.
Collapse
Affiliation(s)
- Charlotte M Verolet
- Pediatric Infectious Diseases Unit, Division of General Pediatrics, Department of Pediatrics, University Hospitals of Geneva & University of Geneva Medical School, Geneva, Switzerland,
| | | |
Collapse
|
3
|
|
4
|
Baldacci ER, Fagundes SN, Koch VHK. Avaliação da suscetibilidade à varicela no paciente pediátrico portador de insuficiência renal crônica. REVISTA PAULISTA DE PEDIATRIA 2008. [DOI: 10.1590/s0103-05822008000100004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
OBJETIVO: Avaliar a suscetibilidade natural à varicela de crianças e adolescentes portadores de insuficiência renal crônica (IRC). MÉTODOS: Estudo transversal de 83 pacientes com idade acima de 18 meses e inferior a 18 anos, durante 2000 e 2001, com ritmo de filtração glomerular (RFG) abaixo de 70mL/min/1,73m², portando cartão vacinal preconizado pela Fundação Nacional de Saúde e que não receberam nenhuma dose da vacina específica. Do total, três pacientes (3/83) foram excluídos, por terem recebido doses da vacina por meio de órgãos não governamentais. A sorologia foi realizada pelo método Enzyme-Linked Immuno Sorbent Assay, considerando-se títulos sorológicos protetores acima de 100mUA/mL. RESULTADOS: Os pacientes renais crônicos tinham idade mediana de 11 anos, 66% eram masculinos, 60% procedentes do próprio município de São Paulo, com RFG médio de 33,6mL/min/1,73m². O diagnóstico clínico de varicela por profissional médico ocorreu em 39 pacientes; destes, 10% se mostraram soronegativos. Dos 80 pacientes restantes, 21 (26%) apresentaram títulos não protetores para varicela. A prevalência de suscetibilidade em menores de seis anos foi 7,93 (IC95%=3,29-19,12) vezes superior à de maiores de seis anos. CONCLUSÕES: Houve diminuição da suscetibilidade à varicela com a idade. Pacientes abaixo de seis anos foram cerca de oito vezes mais suscetíveis à varicela que os renais crônicos com idade mais avançada e duas vezes mais suscetíveis do que a população pediátrica brasileira de mesma idade.
Collapse
|
5
|
Luthy KE, Tiedeman ME, Beckstrand RL, Mills DA. Safety of live-virus vaccines for children with immune deficiency. ACTA ACUST UNITED AC 2006; 18:494-503. [PMID: 16999715 DOI: 10.1111/j.1745-7599.2006.00163.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE Conduct an integrative literature review to evaluate the safety and effectiveness of live-virus vaccines, namely, the measles, mumps, rubella, and varicella vaccines, in children who are immune compromised by exogenous medication either posttransplant or while undergoing maintenance chemotherapy for leukemia. DATA SOURCES Medline, MedlinePlus, EBSCO, PubMed, MD Consult, CINAHL, Clinical Pharmacology, ERIC, Biomedical Reference Collection-Basic, Health Source-Consumer Edition, Health Source-Nursing/Academic Edition, Ovid, CANCERLIT, and the Cochrane Library Online. CONCLUSIONS Because measles infection has a low incidence rate in the United States, it may be advisable not to vaccinate children who are immunocompromised and risk side effects of the vaccine. In contrast to measles infection, varicella has a higher incidence rate and poses a more imminent threat to those who are immunocompromised. Children who are immunosuppressed can receive the varicella vaccination; however, they should have regular titers drawn to confirm adequate protection against the disease and should receive boosters as deemed appropriate. IMPLICATIONS FOR PRACTICE The number of solid organ transplant recipients is steadily increasing with more than 600,000 solid organ transplantations worldwide since the first renal transplant in 1954. The steadily increasing numbers of pediatric patients surviving transplantation, coupled with increased life expectancy, accelerate the need for nurse practitioners to understand the management of these delicate patients following release from the transplant unit.
Collapse
Affiliation(s)
- Karlen E Luthy
- College of Nursing, Brigham Young University, Provo, Utah 84602-5432, USA.
| | | | | | | |
Collapse
|
6
|
Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2006; 46:997-1011. [PMID: 16310566 DOI: 10.1053/j.ajkd.2005.08.032] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2005] [Accepted: 08/23/2005] [Indexed: 12/25/2022]
Abstract
In patients with renal disease, infection remains among the most common causes of morbidity and mortality. Alterations in the function of the immune system, as well as unique exposures of this patient population, account for the increased risk. Vaccination is an invaluable tool in preventing many infectious diseases. Unfortunately, responsiveness to vaccination in patients with renal disease can be diminished. In the present review, we examine the available evidence on the use of vaccinations in adult patients at different stages of chronic kidney disease. We address efficacy, clinical outcomes, and potential costs of individual vaccinations and provide our recommendations based on the literature reviewed. We also identify areas in which additional research is needed.
Collapse
Affiliation(s)
- Mara Dinits-Pensy
- Department of Medicine, Center for Vaccine Development, University of Maryland Medical Center, Baltimore, MD, USA.
| | | | | | | |
Collapse
|
7
|
Chesney RW, Brewer E, Moxey-Mims M, Watkins S, Furth SL, Harmon WE, Fine RN, Portman RJ, Warady BA, Salusky IB, Langman CB, Gipson D, Scheidt P, Feldman H, Kaskel FJ, Siegel NJ. Report of an NIH task force on research priorities in chronic kidney disease in children. Pediatr Nephrol 2006; 21:14-25. [PMID: 16252095 DOI: 10.1007/s00467-005-2087-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2005] [Revised: 06/09/2005] [Accepted: 08/04/2005] [Indexed: 12/19/2022]
Affiliation(s)
- Russell W Chesney
- Department of Pediatrics, University of Tennessee Health Science Center, 50 North Dunlap, 38103-4909, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Chaves TDSS, Lopes MH, de Souza VAUF, Dos Santos SDS, Pereira LM, Reis AD, David-Neto E. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant 2005; 9:192-6. [PMID: 15787792 DOI: 10.1111/j.1399-3046.2005.00279.x] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The severity of varicella-zoster virus (VZV) in immunocompromised children, especially in those receiving renal transplants, is well known. However, the use of live attenuated virus vaccine in this population is controversial. This study aimed to: (i) assess the immunization status of pediatric renal transplant recipients at our center; (ii) determine the anti-VZV antibody titers in such patients; (iii) evaluate the response to VZV vaccine in seronegative children and in those who present low antibody titers (defined as <500 mAU/mL). Vaccinated children were monitored for adverse effects for 8 wk after vaccination. Fifty patients with a mean age of 13.7 yr (range, 3-17 yr) were enrolled. In 49, blood samples were collected and antibodies were screened using ELISA. Seropositivity to VZV was found in 43 (88%), and antibody titers were >/=500 mAU/mL in 37 (75.5%). Of the 12 children who were eligible for vaccination and had antibody titers <500 mAU/mL, one developed varicella before vaccination, two did not meet the inclusion criteria, and three parents refused the vaccination. In the six vaccinated children, there were no adverse reactions to the vaccine, and four (66.6%) responded with anti-VZV titers >/=500 mAU/mL 6-8 wk after vaccination. In conclusion, after renal transplantation, varicella vaccine is safe with a 66% rate of conversion to high antibody titers.
Collapse
Affiliation(s)
- Tânia do Socorro Souza Chaves
- Division of Infectious and Parasitic Diseases, Hospital das Clinicas, University of São Paulo School of Medicine, São Paulo, Brazil
| | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
The prevention of systemic viral and bacterial infections by effective vaccination represents an essential task of pediatric nephrologists caring for children with chronic renal failure (CRF) undergoing renal transplantation (RTPL) with life-long immunosuppression. This review addresses three issues: risk of vaccine-preventable diseases, safety, immunogenicity, and clinical efficacy of available vaccines, and implementation of immunization guidelines. Infections (including vaccine-preventable infections) represent the leading cause of morbidity and mortality in children on dialysis and after RTPL. Vaccination in children with CRF and after RTPL is safe and does not cause reactivation of an immune-related renal disease or rejection after RTPL. Children with CRF generally produce protective serum antibodies to primary vaccinations with killed or component vaccines and live virus vaccines; some children on dialysis and after RTPL may not respond optimally, requiring repeated vaccination. Proof of vaccine efficacy is absence of disease, which can only be confirmed in large cohort studies. A few observational studies provide evidence that vaccination has contributed significantly, at least in the western hemisphere, to the low prevalence of vaccine-preventable diseases among children with CRF. Close cooperation between the local pediatrician/practitioner and the pediatric nephrologist is essential for successful implementation of the vaccination schedule.
Collapse
Affiliation(s)
- Thomas J Neuhaus
- Nephrology Unit, University Children's Hospital, Steinwiesstrasse 75, 8032 Zurich, Switzerland.
| |
Collapse
|
10
|
Sartori AMC. A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis 2004; 8:259-70. [PMID: 15325594 DOI: 10.1016/j.ijid.2003.09.006] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2003] [Accepted: 09/18/2003] [Indexed: 10/26/2022] Open
Abstract
BACKGROUND Individuals with underlying cell-mediated immunodeficiency disorders are at high risk of developing severe, life-threatening illness associated with varicella-zoster virus infection. A live-attenuated varicella vaccine is recommended for routine childhood immunisation in some countries. In healthy children, the vaccine is efficacious and safe but because immunocompromised individuals may be unable to limit replication of live-attenuated vaccine viruses, the varicella vaccine is not recommended for them and there are few exceptions. OBJECTIVES The purpose of this paper is to review the published studies addressing the use of the varicella vaccine in people with cell-mediated immunodeficiency disorders. METHODS A computerised search on the PubMed database was used to collect the relevant papers published up to March 2003. RESULTS The varicella vaccine has been extensively studied in susceptible children with acute lymphoblastic leukaemia in remission, but studies involving individuals with other immunodeficiency disorders are scarce. Some of the current recommendations are based on very few and small studies with short follow-up. Immunocompromised individuals should be given the varicella vaccine only with complete knowledge of their clinical and immunological conditions and after considering the risks of natural infection and vaccination.
Collapse
Affiliation(s)
- Ana Marli Christovam Sartori
- Clinic of Infectious and Parasitic Diseases, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP, Brazil.
| |
Collapse
|
11
|
Robinson J. Efficacy of pneumococcal immunization in patients with renal disease--what is the data? Am J Nephrol 2004; 24:402-9. [PMID: 15273446 DOI: 10.1159/000079883] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2004] [Accepted: 05/25/2004] [Indexed: 12/20/2022]
Abstract
BACKGROUND/AIMS There is an increased incidence of invasive pneumococcal disease in patients with renal allografts, chronic renal insufficiency (CRI), or nephrotic syndrome (NS). Routine pneumococcal immunization (PI) has been recommended for these patients, but the efficacy of PI in this population is not well established. METHODS A review was done of studies that reported the immunologic response, efficacy, or safety of PI in patients with renal allografts, CRI, or NS. RESULTS On review of 26 published studies of PI in this population, all studies demonstrated a serologic response by the majority of patients to at least some pneumococcal serotypes. Use of steroids did not alter this response. In the studies with a greater than 6-month follow-up, declining antibody titers were consistently reported, and this decline was usually more rapid than in healthy controls. However, because the studies of the efficacy of PI in this population involve small numbers of patients and are not controlled, the significance of this decline in titers is not known. The incidence of serious adverse reactions to PI is very low. CONCLUSION Pending more data, patients with renal transplants, CRI, or NS should continue to be offered PI.
Collapse
Affiliation(s)
- Joan Robinson
- Department of Pediatrics, University of Alberta, Edmonton, Alta., Canada.
| |
Collapse
|
12
|
Abstract
The array of immunizations commonly used in childhood has risen in an attempt to prevent many of the potentially serious infections of infancy and childhood. In this article, the authors provide rational guidelines for vaccination of these children. The authors briefly review the susceptibilities caused by immunosuppression in these patients, discuss the problems with various immunizations, and make individual recommendations regarding the use of each vaccine. Most recommendations are based on inferences from populations that may not be directly comparable to the transplantation population (patients with HIV or cancer or patients who have undergone bone marrow transplant), from case reports, and from small series of patients. The best recommendations ultimately must await the results of controlled trials of immunization.
Collapse
Affiliation(s)
- M James Lopez
- Department of Pediatrics, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0718, USA.
| | | |
Collapse
|
13
|
Iglesias Berengue J, López Espinosa J, Campins Martí M, Ortega López J, Moraga Llop F. [Vaccinations and solid-organ transplantation: review and recommendations]. An Pediatr (Barc) 2003; 58:364-75. [PMID: 12681186 DOI: 10.1016/s1695-4033(03)78071-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
Pediatric solid-organ transplant recipients are at high risk for various infectious diseases. Many children are not fully vaccinated before transplantation. To reduce the risk of morbidity and mortality from vaccine-preventable disease, physicians treating pediatric solid-organ transplant recipients should monitor the immunization status of these patients. Consensus on the most appropriate immunization schedule for solid-organ transplant recipients is lacking. Therefore, we provide a review of the currently available data on immunization safety and efficacy and describe strategies to avoid vaccine-preventable diseases in pediatric solid-organ transplant recipients.
Collapse
Affiliation(s)
- J Iglesias Berengue
- Equipo de Trasplante Hepático Pediátrico. Hospital Universitario Vall d'Hebron. Barcelona. España.
| | | | | | | | | |
Collapse
|
14
|
Kalman S, Bakkaloglu SA, Ozkaya O, Buyan N, Söylemezoglu O. Measles: a rare communicable disease in a child with renal transplantation. Pediatr Transplant 2002; 6:432-4. [PMID: 12390433 DOI: 10.1034/j.1399-3046.2002.02028.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Measles is a rare communicable disease which may be fatal in renal transplant patients. Herein we present a patient with renal transplantation who had measles and who subsequently developed subacute measles encephalitis 4 months later. We recommend all children with chronic renal failure be vaccinated against measles before transplantation.
Collapse
Affiliation(s)
- Süleyman Kalman
- Department of Pediatric Nephrology, Gazi University Faculty of Medicine, Besevler 06500, Ankara, Turkey
| | | | | | | | | |
Collapse
|
15
|
Abstract
Existing studies support the use of varicella vaccine in a two-dose regimen in patients with renal disease prior to transplantation. Levels of anti-varicella zoster virus antibody should be monitored on a regular basis after immunization, and where a loss of a previously protective antibody titer occurs, a third booster dose should be considered pretransplant. Further data need to be collected regarding the use of the vaccine in seronegative patients who have already undergone transplantation.
Collapse
Affiliation(s)
- Susan L Furth
- Department of Pediatrics, the Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
| | | |
Collapse
|
16
|
Batiuk TD, Bodziak KA, Goldman M. Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transplant 2002; 16:1-8. [PMID: 11982608 DOI: 10.1034/j.1399-0012.2002.00101.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Definitive approaches to most infectious diseases following renal transplantation have not been established, leading to different approaches at different transplant centers. To study the extent of these differences, we conducted a survey of the practices surrounding specific infectious diseases at US renal transplant centers. A survey containing 103 questions covering viral, bacterial, mycobacterial and protozoal infections was developed. Surveys were sent to program directors at all U.S. renal transplant centers. Responses were received from 147 of 245 (60%) transplant centers and were proportionately represented all centers with respect to program size and geographical location. Pre-transplant donor and recipient screening for hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) and cytomegalovirus (CMV) is uniform, but great discrepancy exists in the testing for other agents. HCV seropositive donors are used in 49% of centers. HIV seropositivity remains a contraindication to transplantation, although 13% of centers indicated they have experience with such patients. Post-transplant, there is wide variety in approach to CMV and Pneumocystis carinii (PCP) prophylaxis. Similarly divergent practices affect post-transplant vaccinations, with 54% of centers routinely vaccinating all patients according to customary guidelines in non-transplant populations. In contrast, 22% of centers indicated they do not recommend vaccination in any patients. We believe an appreciation of the differences in approaches to post-transplant infectious complications may encourage individual centers to analyse the results of their own practices. Such analysis may assist in the design of studies to answer widespread and important questions regarding the care of patients following renal transplantation.
Collapse
Affiliation(s)
- Thomas D Batiuk
- Department of Medicine, Indiana University Medical Center, Indianapolis, USA.
| | | | | |
Collapse
|
17
|
Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis 2001; 33 Suppl 1:S15-21. [PMID: 11389517 DOI: 10.1086/320899] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Pretransplant screening affords an important opportunity to detect and treat preexisting active infection in the solid-organ transplant recipient. In this article, pretransplant strategies for preventing infections after solid-organ transplantation are reviewed. In addition to the search for active preexisting infection in the transplant candidate, immunization remains a cornerstone of preventive practice. Because there is a suboptimal response to vaccinations in patients who are receiving immunosuppressive therapy, as well as in patients with end-stage organ dysfunction, standard immunization of the transplant candidate should be updated as early as possible in the course of the illness, including pneumococcal, influenza, and hepatitis B vaccines. Liver transplant candidates should receive hepatitis A vaccine, and children should receive Haemophilus influenzae type B conjugate vaccine. All nonimmune pretransplant patients should be considered candidates for the varicella vaccine. The management of special risk groups is discussed in detail.
Collapse
Affiliation(s)
- R K Avery
- Department of Infectious Diseases, Cleveland Clinic Foundation, Cleveland, OH, USA.
| | | |
Collapse
|
18
|
Pandya A, Wasfy S, Hébert D, Allen UD. Varicella-zoster infection in pediatric solid-organ transplant recipients: a hospital-based study in the prevaricella vaccine era. Pediatr Transplant 2001; 5:153-9. [PMID: 11422816 DOI: 10.1034/j.1399-3046.2001.00048.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We reviewed 58 cases of varicella-zoster infection that occurred between 1988 and 1998 in 47 pediatric solid-organ transplant recipients. The median age of patients at the time of admission with varicella-zoster infection was 8.0 yr (range 1-17 yr). The median interval between transplantation (Tx) and varicella-zoster virus (VZV) infection was 1.6 yr (range 0.06-9.3 yr). Varicella infection occurred at a rate of one case for every seven transplant recipients. Among the 58 cases of VZV infection, 53% were varicella while 47% were herpes-zoster. Varicella infection occurred despite treatment with varicella-zoster immune globulin (VZIG) in 17 of 31 cases of varicella infection. However, the disease was generally mild with severe disease occurring in only two patients. One patient (1.7%) died as a result of bacterial sepsis. There was no significant relationship between VZV infection and specific immune suppressants. Episodes of rejection were more likely to be temporally associated with the occurence of herpes zoster than with varicella infection (p = 0.02). The data generated provide useful background information in our population in the prevaricella vaccine era.
Collapse
Affiliation(s)
- A Pandya
- The Department of Pediatrics, Divisions of Infectious Diseases,The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
| | | | | | | |
Collapse
|
19
|
Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2001. [PMID: 11044969 DOI: 10.1681/asn.v11suppl_1s1] [Citation(s) in RCA: 392] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Many complications after renal transplantation can be prevented if they are detected early. Guidelines have been developed for the prevention of diseases in the general population, but there are no comprehensive guidelines for the prevention of diseases and complications after renal transplantation. Therefore, the Clinical Practice Guidelines Committee of the American Society of Transplantation developed these guidelines to help physicians and other health care workers provide optimal care for renal transplant recipients. The guidelines are also intended to indirectly help patients receive the access to care that they need to ensure long-term allograft survival, by attempting to systematically define what that care encompasses. The guidelines are applicable to all adult and pediatric renal transplant recipients, and they cover the outpatient screening for and prevention of diseases and complications that commonly occur after renal transplantation. They do not cover the diagnosis and treatment of diseases and complications after they become manifest, and they do not cover the pretransplant evaluation of renal transplant candidates. The guidelines are comprehensive, but they do not pretend to cover every aspect of care. As much as possible, the guidelines are evidence-based, and each recommendation has been given a subjective grade to indicate the strength of evidence that supports the recommendation. It is hoped that these guidelines will provide a framework for additional discussion and research that will improve the care of renal transplant recipients.
Collapse
Affiliation(s)
- B L Kasiske
- Division of Nephrology, Hennepin County Medical Center, University of Minnesota, Minneapolis 55415, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Olson AD, Shope TC, Flynn JT. Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation. Pediatr Transplant 2001; 5:44-50. [PMID: 11260488 DOI: 10.1034/j.1399-3046.2001.00032.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Because of the severe complications that may result from varicella zoster virus (VZV) infection following renal transplantation (Tx), transplanted varicella-susceptible children exposed to varicella are typically given varicella zoster immunoglobulin (VZIG) as prophylaxis or are admitted and treated with parenteral acyclovir if VZIG prophylaxis fails. As both VZIG and hospitalization are costly, prevention of varicella infection by vaccination could potentially result in significant cost savings in addition to decreasing morbidity and mortality. To test this hypothesis, we developed a decision-analysis model to evaluate the cost-effectiveness of vaccinating patients with chronic renal failure (CRF) against varicella prior to renal transplant. Under baseline assumptions, vaccination for varicella pretransplant was a cost-effective strategy, with a cost of $211 per patient vaccinated compared with $1,828 per patient not vaccinated. The magnitude of cost savings from vaccination was sensitive to variations in the cost of varicella vaccine, the percentage of patients hospitalized for treatment with acyclovir, and the percentage of patients exposed to varicella infection. One- and two-way sensitivity analyses confirmed that vaccination was the dominant cost-effective strategy under all conditions examined. We conclude that vaccination for varicella pretransplant is cost-effective for patients with CRF, and that the magnitude of cost savings is sensitive to the cost of hospitalization, the percentage of patients exposed to varicella, and the cost of varicella vaccination. Pending results of ongoing studies of the safety and efficacy of VZV vaccine in children with CRF, we recommend that VZV vaccine be given to all children with CRF.
Collapse
Affiliation(s)
- A D Olson
- Division of Pediatric Gastroenterology, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, USA.
| | | | | |
Collapse
|
21
|
Burroughs M, Moscona A. Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis 2000; 30:857-69. [PMID: 10852737 DOI: 10.1086/313823] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/1999] [Revised: 11/17/1999] [Indexed: 01/19/2023] Open
Abstract
Organ transplantation has evolved from an experimental procedure to an accepted treatment for otherwise irreversible or congenital disorders. The immunosuppression necessary to prevent rejection enhances the severity of many infectious diseases and may potentially attenuate the response to vaccines designed to prevent disease. In spite of the frequency and severity of infectious diseases in organ transplant recipients, many children are not fully vaccinated before transplantation. The safety and efficacy of many of the currently available vaccines for solid organ transplant recipients have not been evaluated. We review the currently available data on immunization safety and efficacy, discuss experimental vaccines, and outline strategies to avoid vaccine-preventable diseases in pediatric organ transplant recipients.
Collapse
Affiliation(s)
- M Burroughs
- Department of Pediatrics, Division of Pediatric Infectious Diseases, Recanati-Miller Transplant Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.
| | | |
Collapse
|
22
|
Kazancioğlu R, Sever MS, Yüksel-Onel D, Eraksoy H, Yildiz A, Celik AV, Kayacan SM, Badur S. Immunization of renal transplant recipients with pneumococcal polysaccharide vaccine. Clin Transplant 2000; 14:61-5. [PMID: 10693637 DOI: 10.1034/j.1399-0012.2000.140111.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Streptococcus pneumoniae, a common pathogen leading to pneumonia, is a cause of morbidity and mortality in immunosuppressed patients. Vaccination against this agent can be recommended for immunosuppressed patients, including those with chronic renal failure, nephrotic syndrome and renal transplant recipients; however, a diminished immune response and loss of protective antibodies have been observed. PATIENTS AND METHODS In our prospective study, the efficacy and side effects of polyvalent pneumococcal vaccination were investigated in renal transplant recipients. A total of 21 patients (6 female, 15 male) with well-functioning renal allografts, who had transplant surgery at least 2 months before, were included in the study. The patients were stratified according to the immunosuppressive protocol and 8 received double, while 13 received triple, immunosuppressive agents. After obtaining basal serum samples, all cases were vaccinated with the 0.5 mL intramuscular administration of polyvalent polysaccharide pneumococcal vaccine (Pneumo 23 Pasteur Merieux, lot No: K 1131). RESULTS Following a mean of 6 wk in all patients and also a mean of 12 wk in 12 patients, serum samples were again obtained to measure pneumococcal antibodies. Antibody titers following 6 and 12 wk of vaccination were significantly higher, as compared with basal values in all patients, except one. These titers did not show any statistically significant difference between double and triple therapies. There was no significant difference between the 12th and 6th wk postvaccination antibody titers. No systemic or local adverse effects were observed. CONCLUSION Pneumococcal vaccination is safe and effective in patients with well-functioning renal allografts, at least in the short term. This vaccination policy may be useful for preventing invasive pneumococcal disease in immunosuppressed patients.
Collapse
Affiliation(s)
- R Kazancioğlu
- Istanbul School of Medicine, Department of Nephrology, Turkey.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Webb NJ, Fitzpatrick MM, Hughes DA, Brocklebank TJ, Judd BA, Lewis MA, Postlethwaite RJ, Smith PA, Corbitt G. Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group. Arch Dis Child 2000; 82:141-3. [PMID: 10648369 PMCID: PMC1718197 DOI: 10.1136/adc.82.2.141] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
OBJECTIVES To investigate the seroconversion rate and duration of persistence of protective antibody titres after varicella immunisation in children with renal failure. DESIGN 32 children (25 end stage and 7 pre-end stage renal failure) were immunised using 2 x 2,000 plaque forming unit doses of varicella vaccine 3 months apart. Varicella antibody titres were measured by enzyme linked immunosorbent assay. RESULTS All children initially seroconverted after immunisation. At a mean follow up of 20.3 months, 23 of 28 had protective antibody titres, 4 children having died of unrelated causes. Two children required a third booster dose. 11 children underwent renal transplantation; 10 had protective titres at the time of transplantation and, at a mean of 23.4 months after immunisation, 6 currently have protective titres. Minor side effects occurred after 11 vaccine doses in 9 children. No child developed varicella, despite 10 clear episodes of exposure to the wild-type virus. CONCLUSIONS Varicella immunisation in children with end stage and pre-end stage renal failure results in a high rate of seroconversion and persistence of protective antibody titres. More widespread use of the vaccine before renal transplantation is recommended.
Collapse
Affiliation(s)
- N J Webb
- Department of Paediatric Nephrology, Royal Manchester Children's Hospital, Pendlebury, Manchester M27 4HA, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Pedrazzi C, Ghio L, Balloni A, Panuccio A, Foti M, Edefonti A, Assael BM. Duration of immunity to diphtheria and tetanus in young kidney transplant patients. Pediatr Transplant 1999; 3:109-14. [PMID: 10389132 DOI: 10.1034/j.1399-3046.1999.00013.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
A considerable proportion of patients with renal transplant, evaluated many years after transplant, lack protective diphtheria antibody levels, despite primary immunization, but maintain immunity to tetanus. These patients respond to a diphtheria and tetanus booster but the duration of the response is uncertain. This study was undertaken to assess if protective antibodies evoked by primary immunization are lost quickly after transplantation, and whether the extent of the immune response to a booster influences the persistence of protective antibodies. We studied 15 patients (group 1) immediately after renal transplant and 35 patients with renal transplant for 6 +/- 4 yr who received a diphtheria and tetanus booster (group 2). Six patients (40%) of group 1 lost protective diphtheria antibodies a median time of 6.5 months after transplant. Thirty-three patients of group 2 responded to the booster with normal diphtheria antibody titers (> 1 IU/mL) in 22 cases and with low titers in 11. Four of the latter lacked immunity to diphtheria at 12 months follow-up. All patients with normal immunity maintained protective levels of diphtheria antibodies. The low responders had a creatinine clearance of 50 +/- 20 mL/min/1.73 m2. Tetanus immunity was maintained in almost all patients of both groups. In conclusion, renal transplant patients had an accelerated loss of diphtheria antibodies in the early post-transplant period. Response to a diphtheria booster identified a group at particular risk, namely the low responders, who may require frequent booster doses. This group had significantly poorer renal function than the normal responders.
Collapse
Affiliation(s)
- C Pedrazzi
- Clinica Pediatrica II, University of Milan, Italy
| | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
A live varicella vaccine has been licensed in Japan, Korea, some European countries, and the United States. Susceptible children can receive varicella vaccine at 12 to 18 months of age, and those who lack a reliable history of chickenpox should be immunized between 11 and 12 years of age. Susceptible children 13 years of age or older should receive two doses at least 1 month apart. Varicella vaccine administered under routine conditions has been proved to be highly effective. Varicella immunization has induced long-term humoral and cellular immunity. The varicella vaccine can be given in immunocompromized children, including children with leukemia and bone marrow transplantation recipients, when immune function recovers. Inactivated varicella vaccine can also reduce morbidity due to varicella zoster virus reactivation in high-risk populations.
Collapse
|
26
|
Kelley SD, Gregory GA. Pediatric solid organ transplantation. Curr Opin Anaesthesiol 1998; 11:289-94. [PMID: 17013234 DOI: 10.1097/00001503-199806000-00009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Solid organ transplantation offers hope for long-term survival and more normal lifestyles for children. Many of the procedures used are scaled-down versions of those used in adults and are associated with distinct challenges in children. Recent studies have provided insights into how transplantation can best serve these patients.
Collapse
Affiliation(s)
- S D Kelley
- Department of Anaesthesia and Pediatrics, University of California, San Francisco, CA 94143, USA
| | | |
Collapse
|